S027 Molecular Markers of Oral Squamous Cell Carcinogenesis—From Gene Chips to Tissue Microarrays

tial response) vs 80% of patients in the other groups. A median survival of 48 months was observed in patients with low-risk biomarkers vs 25 months in patients with high-risk biomarkers (P=.18). Conclusions: In our data set of advanced laryngeal cancer patients, p53 and Bcl-xL together define groups with different risk profiles. Tumor expression of low p53 and low Bcl-xL is a strong predictor of larynx preservation in patients treated with induction chemotherapy followed by radiation therapy in responding tumors.